title: Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system.
abstract: BACKGROUND
  The management of Merkel cell carcinoma (MCC) has been complicated by a lack of detailed prognostic data and by the presence of conflicting staging systems.
  
  
  OBJECTIVE
  We sought to determine the prognostic significance of tumor size, clinical versus pathologic nodal evaluation, and extent of disease at presentation and thereby derive the first consensus staging/prognostic system for MCC.
  
  
  METHODS
  A total of 5823 prospectively enrolled MCC cases from the National Cancer Data Base had follow-up data (median 64 months) and were used for prognostic analyses.
  
  
  RESULTS
  At 5 years, overall survival was 40% and relative survival (compared with age- and sex-matched population data) was 54%. Among all MCC cases, 66% presented with local, 27% with nodal, and 7% with distant metastatic disease. For cases presenting with local disease only, smaller tumor size was associated with better survival (stage I, ≤2 cm, 66% relative survival at 5 years; stage II, >2 cm, 51%; P < .0001). Patients with clinically local-only disease and pathologically proven negative nodes had better outcome (76% at 5 years) than those who only underwent clinical nodal evaluation (59%, P < .0001).
  
  
  CONCLUSIONS
  The National Cancer Data Base does not capture disease-specific survival. Overall survival for patients with MCC was therefore used to calculate relative survival based on matched population data.
  
  
  CONCLUSIONS
  Although the majority (68%) of patients with MCC in this nationwide cohort did not undergo pathologic nodal evaluation, this procedure may be indicated in many cases as it improves prognostic accuracy and has important treatment implications for those found to have microscopic nodal involvement.
authors.affiliation: Department of Medicine/Dermatology, University of Washington, Seattle, Washington, USA.
authors.forename: Bianca D
authors.initials: BD
authors.lastname: Lemos
authors.forename: Barry E
authors.initials: BE
authors.lastname: Storer
authors.forename: Jayasri G
authors.initials: JG
authors.lastname: Iyer
authors.forename: Jerri Linn
authors.initials: JL
authors.lastname: Phillips
authors.forename: Christopher K
authors.initials: CK
authors.lastname: Bichakjian
authors.forename: L Christine
authors.initials: LC
authors.lastname: Fang
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Johnson
authors.forename: Nanette J
authors.initials: NJ
authors.lastname: Liegeois-Kwon
authors.forename: Clark C
authors.initials: CC
authors.lastname: Otley
authors.forename: Kelly G
authors.initials: KG
authors.lastname: Paulson
authors.forename: Merrick I
authors.initials: MI
authors.lastname: Ross
authors.forename: Siegrid S
authors.initials: SS
authors.lastname: Yu
authors.forename: Nathalie C
authors.initials: NC
authors.lastname: Zeitouni
authors.forename: David R
authors.initials: DR
authors.lastname: Byrd
authors.forename: Vernon K
authors.initials: VK
authors.lastname: Sondak
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Gershenwald
authors.forename: Arthur J
authors.initials: AJ
authors.lastname: Sober
authors.forename: Paul
authors.initials: P
authors.lastname: Nghiem
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015266:Carcinoma, Merkel Cell / Q000401:mortality* / Q000473:pathology*; D032921:Consensus; D016208:Databases, Factual; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods* / Q000592:standards; D011379:Prognosis; D015203:Reproducibility of Results; D012878:Skin Neoplasms / Q000401:mortality* / Q000473:pathology*; D016019:Survival Analysis